

# Index

Note: Page numbers of article titles are in **bold face type**.

- ACID-BASE alterations in massive transfusion, 210-211
- Afibrinogenaemia, 124
- AHF concentrates, human, 117
- AHF preparations, animal, 118-119
- Albumin, 22
- Albumin concentrates, use of in hypoproteinaemic states, **135-146**
- Albuminoid fractions, plasma and, 20-22
- Allergic reaction to plasma transfusion, 128-129
- Ammonia and phosphate levels, elevated, 217
- Amniotic fluid examination, in haemolytic disorders, 155-157
- Anaemia—
  - haemolytic, 130
  - plastic, and platelet transfusion, 72
- Antenatal assessment of severity of haemolytic disease, 153-157
- Antibacterial defences, impaired, 215-216
- Anti-D, 25
- Anti-hepatitis B, 26
- Anti-rubella, 26
- Anti-tetanus, 25-26
- ATP, maintenance of, 37
- Autologous blood, 39-40
  
- BACTERIOLOGY, and processed frozen blood, 60-61
- Biochemistry of red cells, 58-59
- Blood—
  - attainment of self-sufficiency from donation rates, 27-28
  - autologous, 39-40
  - compatible non-identical, 40
  - definition of the nature of the need for, 7-8
  - demand for blood products, 17-27
  - genotyped, 40
  - platelet rich, 39
  - resuspension of deglycerolised, 57-58
  - supply of human, 14-17
  - transfusion of frozen, 62-64
  - unmatched, 40
  - whole, 19, 38-41
- Blood and blood products, some complications associated with the administration of, **165-180**
- Blood coagulation factor, management of acquired deficiencies of, 127-128
- Blood donor, the voluntary, **3-11**
- Blood donor organisation, 8-11
- Blood examination in haemolytic disease, 153-155
- Blood products, pharmacological agents in, 177-178
- Blood replacement, massive, 73
- Blood transfusion—
  - and transmissible disease, **183-198**
  - and tropical diseases, 196-198
  - massive, **201-219**
  - problems of supply and demand, **13-31**
  - (see also under Transfusion)
- Brucellosis, transfusion transmitted, 195-196
  
- CARDIAC surgery and platelet transfusion, 73
- Cell separation technique, the choice of, 91
- Cell separators, centrifugal, 82-83
- Cell yields, granulocyte, 84
- Cells—
  - buffy coat poor packed, 44
  - buffy coat rich packed, 44
  - chronic granulocyte leukaemia, 88-89
  - leucocyte and platelet poor, 45-46
  - new liquid preservatives for packed, 46
- Cellular elements, demand for, 19-20
- Centrifugal cell separators, 82-83
- Chagas' disease, transfusion transmitted, 198
- Christmas disease and its management, 121-123
- Chronic granulocytic leukaemia cell transfusion, complications of, 88-89
- Chronic granulocytic leukaemia cells, 88
- Citrate toxicity, 203
- Coagulation abnormalities, 205-206
- Coagulation defects, less common inherited, 124-126
- Coagulation factor therapy, **113-130**
- Coagulation factors, 22-24
- Cryoprecipitate and haemophilia, 116

- DEFIBRINATION syndrome, 127-128  
 Diseases, transmission of communicable, 184-196, 217  
 Dysfibrinogenaemia, 124  
 2,3-DPG, maintenance of, 37-38
- EXCHANGE transfusion, mathematics of, 201-203
- FACTOR I, 22  
 Factor V deficiency, 125  
 Factor VII deficiency, 125-126  
 Factor VIII, 22-23  
   antibodies to, 129  
 Factor IX, 23-24  
 Factor IX concentrates and Christmas disease, 122-123  
 Factor X deficiency, 126  
 Factor XIII deficiency, 126  
 Fetus—  
   diagnosing the Rh-negative, 157-159  
   treatment of severely affected, in haemolytic disease, 159-160  
 Fibrinogen, 22  
 Fractionation—  
   hepatitis and, 105-106  
   plasma, 95-110  
 Fractionation methods, 97-105  
 Frozen red cells, 53-65
- GENOTYPED blood, 40  
 Glycerolisation of red cells, 54  
 Granulocyte collection from normal donors, 84-86  
 Granulocyte collection procedures, 82-83  
 Granulocyte donors—  
   effect on blood counts, 85-86  
   side-effects on, 85  
 Granulocytes—  
   behaviour of infused, 87-89  
   filtration, 83  
   irradiation of, 89-90  
   normal cells, 87  
 Granulocytic transfusions—  
   clinical studies of normal, 87  
   complications of normal, 87-88  
   indications for, 89
- HAEMATOLOGY of red cells, 59-60  
 Haemoglobin function, altered, in massive transfusion, 206-210  
 Haemolytic anaemia, 130  
 Haemolytic disease—  
   antenatal assessment of severity of, 153-157  
   Haemolytic disease (*continued*)  
     prevention of, 151-153  
     treatment of severely affected fetus, 159-160  
   Haemophilia and Christmas disease, home treatment of, 123  
   Haemophilia, therapeutic material available for treatment of, 115-119  
   Haemophiliacs who have antibodies to factor VIII, management of, 120-121  
   Haemostasis, relationship between the level of factor VIII in the blood and, 114-115  
   HB<sub>s</sub>Ag, detection and measurement of, 187-193  
   Hepatitis and fractionation, 105-106  
   Hepatitis, transmitted by cytomegalovirus and Epstein-Barr virus, 193-194  
   Hyperkalaemia, 216  
   Hypervolaemia, 128  
   Hypo-albuminaemia, 137-139  
   Hypoproteinaemia, 137-146  
     albumin therapy, 142-146  
     effect of, 139-140  
     treatment, 140-146  
   Hypoproteinaemic states, the use of albumin concentrates in, 135-146  
   Hypothermia, 211
- IMMUNOGLOBULIN, anti-vaccinal, 26  
 Immunoglobulins, 24-27  
 Immunological mishaps, 217-218  
 Infusion of vasoactive substances, 215
- LEUCOCYTE, and transfusion reactions, 170-173  
 Leucocytes, 20  
 Leukaemia—  
   and platelet transfusion, 71-72  
   use of donors with chronic granulocytic, 86
- MATCHING, donor-recipient, 90
- OXYGEN requirements of patients, 34-35
- PATIENT, platelet transfusion and the refractory, 76-77  
 Pharmacological agents in blood products, 177-178  
 Phosphate and ammonia levels, elevated, 217  
 Plasma—  
   and albuminoid fractions, 20-22  
   and Christmas disease, 122

- Plasma (*continued*)  
 and replacement therapy, 115  
 fresh, 20–21  
 outdated, 21  
 storage and transport of fractionation, 97  
 volume fractionated, 96
- Plasma fractionation, **95–110**  
 future of, 109–110
- Plasma fractions, 106–109
- Plasma proteins, and transfusion reactions, 174–177
- Plasticiser toxicity, 213–214
- Platelet destruction disorders, 73
- Platelet dysfunction disorders, 73
- Platelet rich blood, 39
- Platelet therapy, complications of, 173–174
- Platelet transfusion program, organisation of, 69–70
- Platelet transfusions, **69–79**  
 and the refractory patient, 76–77  
 expected increments, 76  
 indications for, 70–73  
 unsolved problems of, 77–79
- Platelets, 20  
 methods of preparation for transfusion, 74–76
- Pregnancy—  
 incidence of maternal sensitisation from, 151  
 transplacental haemorrhage in the complications of, 150
- Preservatives for packed cells, newer liquid, 46
- Protein fraction, purified, 21–22
- Proteins, infusion of denatured, 214–215
- Prothrombin (factor II) deficiency, 125
- Purpura, post-transfusion, and platelet transfusion, 73
- RED** cell, residual materials after washing of, 62
- Red cell and transfusion reactions, 166–170
- Red cell concentrates, choice of, 41–46
- Red cell deformability, impaired, 216–217
- Red cell product—  
 choice of, 35–38  
 quality of, 35–37  
 survival in vivo, 61
- Red cell transfusion, **33–46**  
 assessment of need, 33–35  
 purpose of, 33
- Red cells—  
 characteristics of frozen, thawed and washed, 58–62  
 concentrated, 19–20  
 criterion for adequate and conservative use of, 35  
 filing records of, 55
- Red cells (*continued*)  
 frozen, 53–65  
 gravity or sedimented, 43–44  
 methods of preparing, 43–46  
 processes involved in freezing, thawing and washing, 54–58  
 thawing, 55–56  
 washed, 44–45  
 washing, 56–57
- Replacement therapy—  
 choice of material, 120  
 complications and side-effects of coagulation factor, 128–130  
 duration and frequency of, 120  
 factor VIII level required, 119–120  
 practice of, 119–120  
 principles of, 113–115
- Resuspension of blood, 57–58
- Rh iso-immunisation, observations on past, present and future; **149–161**
- Rh-negative fetus, diagnosing the, 157–159
- STORAGE** of red cells, 54–55
- Syphilis, transfusion transmitted, 194–195
- THROMBOCYTOPENIA**, drug-induced, and platelet transfusion, 72
- Toxoplasmosis, transfusion transmitted, 196
- Transfer factor, 177
- Transfusion—  
 accidental introduction of infective agents, 198  
 platelet, **69–79**  
 red cell, **33–46**  
 single unit, 40–41  
 thrombo-emboli, complications from, 130  
 (*see also* Blood transfusion)
- Transfusion hepatitis, 129
- Transfusion of frozen blood, 62–64  
 clinical experience, 64  
 composition of solutions, 65–66  
 costs, 64–65  
 disadvantages, 63–64  
 indication for use, 62–63  
 manufacturers of equipment, 65
- Transfusion practices, platelet, 76
- Transfusion reactions—  
 and the leucocyte, 170–173  
 investigation of, 178–180  
 plasma proteins and, 174–177  
 red cell and, 166–170
- Transmitted diseases, 217
- Transplacental haemorrhage—  
 and maternal sensitisation, 149–150  
 in Rh-negative women, 150–151  
 in the complications of pregnancy, 150

- Tropical diseases, blood transfusion and, 196-198
- VASOACTIVE substances, infusion of, 215
- Viral hepatitis, transfusion transmitted, 184-187
- Von Willebrand's disease, 123-124
- WHITE cell therapy, **81-91**
- Whole blood, 19  
choice of, 38-41





# Index

Note: Page numbers of article titles are in **bold face** type.

## ACANTHAMOEBA, 339-340

### Antibiotics—

bacteriological requirements for empiric therapy with, 363-365

combined therapy, adverse effects of, 371-372

choice of in neutropenia, 354-356

early therapy of severe infections, 362

as factor predisposing to fungal infection, 258-259

multiple regimens, 369-370

prophylactic programmes, (*see* Protected environment)

synergism in combined use of, 365-368

antimicrobial, experimental evidence of, 368-369

clinical significance of, 372-374

in patients with haematological diseases, 361-375

### Aspergillosis, 278-284

clinical manifestations, 280-281

definition, 278

diagnosis, 281

criteria, 281

negative and positive cultures, meaning of, 281-282

serological tests, 282-283

epidemiology, 279

mechanisms of resistance, 278-279

occurrence, 278

predisposing factors, 279

prevention, 283

therapy, 283-284

drug sensitivity, 283

results of, 283-284

## BACTERIAL infection in haematological diseases, 229-246

immune response in, 457-458

predisposing factors, 229-232

types of, and causative organisms, 232-235

gram-negative organisms, 235-241

gram-positive organisms, 241-242

other organisms, 242-244

## CANDIDIASIS, 268-278

clinical manifestations, 272-273

definitions, 268-269

diagnosis, 273-275

criteria, 273

cultures, 273-274

serology, 275

epidemiology, 271-272

mechanisms of resistance, 269-270

occurrence, 269

predisposing factors, 271

prevention, 275-276

therapy, 276-278

## Chickenpox, 311-313

## Coccidioidomycosis, 295

Corticosteroids as a factor predisposing to cryptococcosis, 289-290

## Cryptococcosis, 287-294

clinical manifestations, 290-291

definition, 287

diagnosis, 291-292

epidemiology, 290

mechanisms of resistance, 288-289

occurrence, 287-288

predisposing factors, 289-290

prevention, 292

treatment, 293

## Cytomegalic inclusion disease, 316-319

## EPSTEIN-BARR virus, 319

## FUNGAL infections, invasive—

aspergillosis, 278-284

candidiasis, 268-278

clinical manifestations, 260-261

coccidioidomycosis, 295

the compromised host, 249-250

cryptococcosis, 287-294

diagnosis of, 261

criteria for, 261-262

method of, 262-264

epidemiology of, 260

fusarium infections, 295

histoplasmosis, 295

- Fungal infections (*continued*)  
 immune response in, 458–460  
 occurrence—  
   in acute leukaemia, 250–252  
   in lymphomas, 252  
   in multiple myeloma, 252–253  
   in chronic lymphocytic leukaemia, 252–253  
 opportunistic invasive, in patients with leukaemia and lymphoma, **249–295**  
 penicillium infections, 295  
 phycomycosis, 284–287  
 predisposing factors, 254–261  
   acute leukaemia, 254–255  
   antibiotics, 258–259  
   chronic lymphocytic leukaemia, 256  
   corticosteroid therapy, 257–258  
   cytotoxic agents, 258  
   Hodgkin's disease, 255–256  
   iron, 259–260  
   multiple myeloma, 256  
   neutropenia, therapy for, 256–257  
   non-Hodgkin's lymphoma, 256  
   nosocomial hazards, 260  
 prevention of, 265  
 therapy, 265–268  
   drugs, 256–267  
   granulocyte transfusions, 267–268  
   results of, 268  
 Fungi, host mechanisms of resistance to, 253–254  
 Fusarium infections, 295
- GLUCOSE-6-phosphate dehydrogenase deficiency, 340  
 Granulocyte transfusions and fungal infections, 267–268
- HEPATITIS, viral, 319–321  
 Hartmannella, 339–340  
 Herpes zoster, 313–314  
 Herpesvirus hominus (herpes simplex), 314–316  
 Histoplasmosis, 295  
 Hodgkin's disease—  
   and cryptococcosis, 287–288, 289  
   as a factor predisposing to fungal infections, 255–256  
 Host defence mechanisms—  
   definition of, 426–427  
   effect of haematological malignancies and their treatment on, **425–442**  
   measurement of, 428–431
- IMMUNE response—  
 B cells, 450  
 cellular events in, 451–452
- Immune response (*continued*)  
 inhibition of, 453–454  
 restoration of, in patients with haematological disorders, 461–462  
 role of cellular and humoral factors in infections, **449–462**  
   bacterial, 457–458  
   fungal, 458–460  
   parasitic, 460  
   viral, 455–457  
 T cells, 450–451
- Immunity—  
 humoral, 452–453  
 test for evaluation of, 455
- Immunodeficiency—  
 in the aetiology of lymphoma and leukaemia, 431–433  
 in lymphoma and leukaemia, 435–439
- Immunosuppression, therapy-induced in lymphoma and leukaemia, 439–441
- Immunotherapy of lymphoma and leukaemia, 441–442
- Influenza, 323
- LEUCOCYTE transfusions in management of infections in neutropenic patients, **379–392**
- Leucocyte collection, 381–384  
 future of, 391–392
- Leukaemia—  
 immunodeficiency in, 435–439  
 immunodeficiency in the aetiology of, 431–433  
 immunological cells of origin in, 433–435  
 immunotherapy of, 441–442  
 invasive fungal infections in, **249–295**  
   cryptococcosis, 287  
   therapy-induced immunosuppression in, 439–441
- Leukaemia, acute, and fungal infections, 250–252, 254–255
- Leukaemia, chronic granulocytic, and fungal infections, 252–253, 256
- Lymphoma—  
 immunodeficiency in, 435–439  
 immunodeficiency in the aetiology of, 431–433  
 immunological cells of origin in, 433–435  
 immunotherapy of, 441–442  
 invasive fungal infections in, **249–295**  
 therapy-induced immunosuppression in, 439–441
- Lymphoma, non-Hodgkin's, and fungal infections, 256
- MALARIA, 340, 342  
 Measles, 321



- Mononucleosis, infectious, 319  
Mumps, 321-322  
Myeloma, multiple, and fungal infections, 252-253, 256
- NATIONAL Cancer Institute study, 410-414  
Neutropenia—  
  antibacterial therapy, special considerations in patients with, 347-358  
  antibiotic therapy and, 354-356  
  bacterial infections during—  
    clinical signs, 350-354  
    incidence, 347-349  
    management, 356-358  
    severity, 349-350  
  fungal infections and, 256-257  
  white blood cell transfusions in infections in patients with, 379-392
- PENICILLIUM infections, 295  
Phycomycosis, 284-287  
  clinical manifestations, 285-286  
  definition, 284  
  diagnosis, 286  
  epidemiology, 285  
  mechanisms of resistance, 284  
  occurrence, 284  
  predisposing factors, 284-285  
  prevention, 286  
  therapy, 287  
Piroplasmiasis, 341  
Pneumocystis carinii pneumonitis, 334-339  
  acid-base profile, 335  
  clinical manifestations, 334-335  
  cultivation, in vitro, 335-336  
  diagnosis, 337-338  
  histopathology, 337  
  the organism, 336-337  
  serological methods, 338  
  treatment, 338-339  
Protected environment and prophylactic antibiotic programmes—  
  clinical studies, 409-423  
  microbiological studies, 395-407  
  National Cancer Institute study, 410-414  
  other studies, 414-421  
Protozoan infections in haematological diseases, 329-345  
  associated with malignancies, 329-340  
    Hartmannella (acanthamoeba), 339-340  
    pneumocystis carinii pneumonitis, 334-339  
    toxoplasmosis, 329-334  
  and glucose-6-phosphate dehydrogenase deficiency, 340  
  and haemoglobinopathies, 340
- Protozoan infections (*continued*)  
  splenectomy, predisposing to, 340-342  
  malaria, 342  
  piroplasmiasis, 341-342
- REMISSION-induction chemotherapy, severe infection during, 412-414  
Rubella, 321  
Rubeola, 321
- SHINGLES, 313-314  
Splenectomy predisposing to protozoan infection, 340-342  
Synergism—  
  between antibiotics used in combination, 365-368  
  clinical significance of, 372-374  
  experimental evidence of, 368-369
- TORULOPSIS glabrata infection, 294-295  
Toxoplasmosis, 329-334  
  clinical manifestations, 330-331  
  diagnosis, 331-333  
  prevention, 333-334  
  treatment, 334  
Transfusions, granulocyte—  
  animal studies, 384  
  fungal infections and, 267-268  
  prophylactic use of, 391-392  
  results of, 385-391  
Transfusions, white blood cell, in management of infections in neutropenic patients, 379-392
- VACCINIA, 322-323  
Varicella, 311-313  
Viral hepatitis, 319-321  
Viral infections and haematological malignancies, 311-324  
  cytomegalic inclusion disease, 316-319  
  herpes zoster (shingles), 313-314  
  herpesvirus hominus (herpes simplex), 314-316  
  immune response in, 455-457  
  infectious mononucleosis (Epstein-Barr Virus), 319  
  influenza, 323  
  mumps, 321-322  
  rubella (German measles, three-day measles), 321  
  rubeola (measles, seven-day measles, red measles), 321  
  vaccinia, 322-323  
  varicella (chicken pox), 311-313  
  viral hepatitis, 319-321



# Index

Note: Page numbers of article titles are in **bold face** type.

- ALCOHOL**—  
and folate malabsorption, 607–608  
and megaloblastic anaemia, 624–625
- Anaemia, megaloblastic, *see* Megaloblastic Anaemia
- Anticonvulsant drug therapy—  
and megaloblastic anaemia, 622–623, 666  
mechanism of folate disturbances in, 670
- Antimicrobial therapy and megaloblastic anaemia, 625
- Ascorbic acid, 538
- Atrophic gastritis—  
aetiology of, 501  
corticosteroids, response to, 513  
immune aspects of, **497–514**  
cell-mediated immunity, 511  
humoral immunity, 511–513  
immune deficiency, 509–510  
intrinsic factor, response to, 502–504  
parietal cell antigen, response to, 504–506  
serum gastrin levels, 510–511
- Autoimmunity in pernicious anaemia and chronic gastritis, 507–514
- B<sub>12</sub>**, *see* Vitamin B<sub>12</sub>
- COBALOPHILIN**—  
chemical properties of, 474–478  
granulocyte, relationship with trans-cobalamins 1 and 3, 477–478  
in disease, 489–490  
nomenclature, 474–478
- Conjugase, intestinal mucosal, 594–595
- Coeliac disease, 652
- Contraceptive agents, oral, and megaloblastic anaemia, 623–624
- Cystathionine synthase, deficiency of, 646–647
- DEOXYRIBONUCLEOSIDE** triphosphates (dNTP), 733–735  
effects of antimetabolite drugs on, 733
- Deoxyribonucleoside (*continued*)  
effects of megaloblastic anaemia on, 734
- Deoxyuridine suppression test (dU test), 539, 751
- Dihydrofolate reductase inhibitors, 621–622
- Dihydropteridine reductase, deficiency of, 649
- DNA polymerases and RNA primer, 731
- DNA synthesis—  
defects in, and megaloblastic anaemia, **727–742**  
activation of DNAases, 738  
defective DNA repair, 735–738  
evidence for, 728  
excess initiation of, over DNA chain elongation, 738–741  
normal mammalian, 729–733  
enzymes required for, 732  
Okazaki fragments, 732  
replicons, 729–731  
RNA primer and DNA polymerases, 731
- EPILEPSY**—  
and folate deficiency, 673–676  
folate and vitamin B<sub>12</sub> metabolism in non-anaemic patients with, 667–670  
bone marrow changes, 667–668  
folate levels, 688–669  
formiminoglutamic acid (FiGlu) excretion, 669  
macrocytosis, 667  
vitamin B<sub>12</sub> levels, 669
- Englena gracilis* assay, 522–530
- FOLATE**—  
composition, synthesis and function in natural materials, **547–563**, 590–592  
congenital malabsorption of, 640–641  
functions of, in the nervous system, 664–666  
in cerebrospinal fluid, 662  
in serum—  
clearance in vitamin B<sub>12</sub> deficiency, 709–710

**Folate (continued)**

- levels in non-anaemic epileptic patients, 668-669
- levels in vitamin B<sub>12</sub> deficiency, 709
- in the brain, 662
- in treatment of megaloblastic anaemia, 760
- radioassay for, in biological fluids, 580-584
- vitamin B<sub>12</sub> interrelations, **697-718**
- Folate absorption—
  - intestinal, 592-603
    - from food, 592
    - hydrolysis, 593-594
    - site of, 594-597
  - quantitative aspects of, 592-593
  - intracellular metabolism, 602
  - quantification of, in man, 603-605, 758
  - transport mechanisms, 597-603
    - location of, 603
    - release from epithelial cells to plasma, 603
- Folate binding proteins, **569-584**
  - identification of, 574-575
  - in erythrocytes, 571
  - in milk, 570-571
  - significance of, 576-577
  - in serum, 571-573
  - significance of, 578-580
  - in tissues, 573-574
  - significance of, 577-578
  - intracellular, significance of, 577-578
  - terminology, 569-570
  - use of, in radioassays for folate, 580-584
- Folate deficiency—
  - caused by unusual diets, 648
  - due to malnutrition, 653
  - in megaloblastic anaemia, 754
  - molecular basis of, 713-715
  - in premature infants, 652
  - neuropsychiatric aspects of, 673-684
    - epileptic patients, 673-676
    - geriatric patients, 679
    - methotrexate encephalopathy, 681
    - other neurological patients, 676-677
    - psychiatric patients, 677-679
- Folate malabsorption—
  - congenital, 640-641
  - due to drug ingestion, 608-610
  - following gastrectomy, 607
  - in alcoholics, 607-608
  - in intestinal mucosal disease, 605-607
  - jejunal factor in, 641
- Folate metabolism—
  - co-enzymes, role of, in one-carbon-unit transfers, 704-707
  - disorders of, in childhood, 631-659

**Folate metabolism (continued)**

- not associated with megaloblastic anaemia, 644-645
  - drugs interfering with, 621-625
    - alcohol, 624-625
    - anticonvulsant, 622-623, 670
    - antimicrobial, 625
    - contraceptive agents, oral, 623-624
    - dihydrofolate reductase inhibitors, 621-622
  - intestinal, 602
  - intracellular, 602
  - mental retardation and inborn errors of, 679-680
  - neurological aspects of, **661-688**
    - anticonvulsant megaloblastic anaemia, 666
    - anti-epileptic and antifolate mechanisms, 671-673
    - CSF folate transport and blood-brain barrier, 662-664
    - in non-anaemic epileptic patients, 667-670
    - see also* Epilepsy, Folate deficiency, neuropsychiatric aspects of 'schizophrenia' and inborn errors of, 680
    - see also* Polyglutamyl folate; Pteroyl derivatives
  - Formiminoglutamic acid (FiGlu), effect of vitamin B<sub>12</sub> deficiency on, 710-711
  - excretion, in non-anaemic patients with epilepsy, 669
- GASTRIN**, serum levels in atrophic gastritis, 510-511
- HAEMOLYTIC** anaemia, predisposing to folate deficiency, 648
- Homocystinuria**, 637-638
  - due to deficiency of cystathionine synthase, 646-647
- Hydrolysis** in folate absorption, 593-597
- Hypoxanthine-guanine phosphoribosyl transferase**, deficiency of, 648
- INTRACELLULAR** cobalamin binding protein (ICB), chemical properties of, 479
- Intrinsic factor**—
  - abnormal or absent in childhood, 633-644
  - chemical properties and nomenclature, 473-474
  - immune response to, in pernicious anaemia and atrophic gastritis, 502-504
  - in disease, 489

- Lactobacillus leichmannii* assay, 530-532  
 Lesch-Nyhan syndrome, 648  
 Leukaemia, chronic myeloid, and serum B<sub>12</sub> levels, 538
- MALNUTRITION and folate deficiency, 653  
 Megaloblastic anaemia—  
   and DNA replication, derangement of, 727-742  
   and pernicious anaemia, 754-755  
   causes of, 752-785  
   chromosome abnormalities and cell death in, 741  
   clinical aspects, 752-753  
   diagnosis of, 747-751  
     biochemical data, 755-756  
     bone marrow examination, 750-751  
     deoxyuridine suppression test, 751  
     folate absorption test, 758  
     mean corpuscular volume (MCV), 747-750  
     peripheral blood film, 750  
     vitamin B<sub>12</sub> absorption tests, 756-758  
   due to anticonvulsant therapy, 666  
   due to B<sub>12</sub> deficiency, 753-754  
     serum B<sub>12</sub> levels in, 526-528  
   due to folate deficiency, 754  
     serum B<sub>12</sub> levels in, 528-529  
   effect on dNTP, 734  
   induced by drugs affecting folate metabolism, 621-625  
     alcohol, 624-625  
     anticonvulsant therapy, 622-624  
     antimicrobial therapy, 625  
     contraceptive agents, oral, 623-624  
     dihydrofolate reductase inhibitors, 621-622  
   induced by drugs affecting vitamin B<sub>12</sub> absorption, 625-626  
     purine antagonists, 626  
   management, 758-760  
   folate therapy, 760  
   intercurrent infection, treatment of, 758-759  
   long-term, 759  
   transfusions, 758  
   vitamin B<sub>12</sub> therapy, 759  
   metabolic abnormalities associated with, 642-643  
   of pregnancy,  
     serum B<sub>12</sub> levels in, 529-530  
 Megaloblastic anaemia in childhood, 631-653  
   due to acquired defects, 650-653  
     defective placental transfer of B<sub>12</sub>, 651  
     intestinal malabsorption of B<sub>12</sub>, 651  
     malnutrition, 653  
   Megaloplastic anaemia in childhood (*continued*)  
     prematurity, 652  
     sprue and coeliac disease, 652  
     due to inherited defects, 631-650  
       intestinal transport of IF and B<sub>12</sub>, disorders of, 634  
       intrinsic factor, abnormal or absent, 633  
       transcobalamin 1, deficiency of, 636  
       transcobalamin 2, deficiency of, 635  
       vitamin B<sub>12</sub>, defective accumulation of, in bone marrow cells, 636-640  
   Methionine, effect of, in vitamin B<sub>12</sub> deficiency, 715-716  
   Methionine adenosyl transferase, deficiency of, 647-648  
   Methotrexate encephalopathy, 681  
   Methylmalonaturia, 637-638  
     congenital, 638-640  
   Methyltetrahydrofolate 'trap' hypothesis, 707  
 Monoglutamyl folate—  
   absorption process, compared with polyglutamyl folate, 597-598  
   mechanism of intestinal epithelial cell uptake, 598-602  
   *see also* Folate absorption
- ONE-carbon-unit transfers, role of folate co-enzymes in, 704-707  
 Okazaki fragments, 732  
 Orotic aciduria, 649
- PARIETAL cell antigen, 504-506  
 Pernicious Anaemia—  
   diagnosis of, 754-755  
     significance of gastric autoimmunity, 507-508  
   gastric lesion in, 498-501  
   genetic studies, 513-514  
   immune aspects of, 497-514  
     cell-mediated immunity, 511  
     humoral immunity, 511-513  
     immune deficiency, 509-510  
     intrinsic factor, response to, 502-504  
   parietal cell antigen, response to, 504-506  
   in childhood, 650  
   serum B<sub>12</sub> levels in 538  
   serum gastrin levels in, 510-511  
 Phenylketonuria, 649  
 Polyglutamyl folate—  
   absorption process, compared to monoglutamyl folate, 597-598  
   biosynthesis and function of, 560-563

Polyglutamyl folate (*continued*)

- size and distribution of, 556-560
  - in food, 560
  - in mammals, 557-559
  - in microorganisms, 559
  - in plants, 559
  - in viruses, 559

*see also* Folate; Folate absorption; Folate metabolism

Pregnancy serum B<sub>12</sub> levels in, and megaloblastic anaemia of, 529-530

## Pteroyl derivatives—

- biosynthesis and function of, 554-556
  - in vitamin B<sub>12</sub> deficiency, 711-713
- distribution of, 547-554
  - in birds, 552
  - in food, 553-554
  - in mammals, 549-552
  - in microorganisms, 553
  - in plants, 553
  - in viruses, 552

## Purine antagonists and megaloblastic anaemia, 626

## Pyrimidine antagonists, and megaloblastic anaemia, 626

## RADIO-ISOTOPE dilution assay (RIDA), 532-538

- intrinsic factor-coated charcoal method, 532-534
- normal serum as binder, 534
- solid-matrix technique, 535
- Transcobalamin 1 as a binder, 535-538

## RNA primer and DNA polymerases, 731

R-type vitamin B<sub>12</sub> binding proteins, *see* Cobalophilin

## 'SCHIZOPHRENIA' and inborn errors of folate metabolism, 680

## Sprue, 652

## Sulphur-containing amino acids, disorders of, 645-647

## TRANSCOBALAMIN 1—

- deficiency of, in childhood, 636
- nomenclature and chemical properties of, 475
- relationship with transcobalamin 3 and granulocyte cobalophilin, 477-478

## Transcobalamin 2—

- chemical properties of, 475, 479
- deficiency of, in childhood, 635
- in disease, 489

## Transcobalamin 3, relationship with trans-

Transcobalamin 3 (*continued*)

- cobalamin 1 and granulocyte cobalophilin, 477-478

## Transfusions, in megaloblastic anaemia, 758

VITAMIN B<sub>12</sub>—

- absorption, drugs interfering with, 625-626

## absorption tests, 756-758

## defective placental transfer of, 651

## enzymatic functions, 699-702

## in treatment of megaloblastic anaemia, 759

## inherited defects in utilisation of, 636-640

## inherited defects of transport and storage of, 635-636

## inherited disorders involving, 633-635

## interrelations with folate, 697-718

## intestinal malabsorption of, in childhood, 651

## serum levels

## assays, 521-540

## deoxyuridine suppression test (dU test), 539

*Euglena gracilis*, 522-530*Lactobacillus leichmannii*, 530-532

## radio-isotope dilution (RIDA), 532-538

## in chronic myeloid leukaemia, 538

## increase of, in pernicious anaemia and chronic myeloid leukaemia, 538

in megaloblastic anaemia due to B<sub>12</sub> deficiency, 526-528

## in megaloblastic anaemia due to folate deficiency, 528-529

## in non-anaemic patients with epilepsy, 669

## in pregnancy and megaloblastic anaemia of pregnancy, 529-530

## reduction of, by ascorbic acid, 538

## significance of, 524-526

## transport of, 480-484

## kinetic aspects, 482-484

Vitamin B<sub>12</sub> binding proteins, 473-490

## deficiency of, 538-539

## determination of, 484-489

## handling of samples, 485

## radioactive preparations, 485

## separation methods, 486

## in disease, 489-491

## intracellular cobalamin (ICB), chemical properties of, 479

## nomenclature and chemical properties of, 473-479

R-type, *see* Cobalophilin*see also* Cobalophilin; Intrinsic factor, Transcobalamin

Vitamin B<sub>12</sub> deficiency—

- cellular folate stores and pteroylpolyglutamate synthesis in, 711–713

- effect of methionine in, 715–716

- effect on formiminoglutamic acid (FiGlu) and other metabolites, 710–711

- in megaloblastic anaemia, 753–754

- molecular basis of megaloblastosis, 713–717

Vitamin B<sub>12</sub> deficiency (*continued*)

- neuropsychiatric complications of, metabolic basis, 684–688

- neurological lesions in, 716–717

- serum folate clearance in, 709–710

- serum folate level in, 709

- unexplained case of, 640

Vitamin B<sub>12</sub> metabolism, 698–699

- neurological aspects of, 661–688